A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study
Abstract
Colony stimulating factors (CSF) are widely prescribed to avoid febrile neutropenia (FN) among cancer patients receiving chemotherapy, but studies show their use is often not consistent with practice guidelines. In addition, there is limited high quality evidence assessing benefits and harms of primary prophylactic-CSF (PP-CSF) in the setting of chemotherapy that poses an intermediate risk of FN. To address these issues, with funding from the Patient Centered Outcomes Research Institute (PCORI) and the National Cancer Institute's Community Oncology Research Program, SWOG is sponsoring a prospective, cluster randomized controlled pragmatic trial of an automated order entry protocol for PP-CSF among patients with breast, lung and colorectal cancer receiving myelosuppressive chemotherapy, with a nested randomized controlled trial of PP-CSF for patients receiving intermediate risk chemotherapy. Primary outcomes include adherence to practice guidelines, overall rates of FN and rates of FN among persons receiving intermediate risk chemotherapy. The study, the first pragmatic trial in the National Cancer Institute's cancer cooperative clinical trials network, will provide critical evidence to inform physician and patient decision-making around PP-CSF use and practice policies regarding automated orders in cancer components.
Formats available
You can view the full content in the following formats:
References
Papers of special note have been highlighted as: • of interest
1.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. 66(1), 7–30 (2016).
2.
Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10), 2258–2266 (2006).
• Study done to better define mortality, length of stay, cost and risk factors associated with mortality and prolonged hospitalization in cancer patients with febrile neutropenia (FN).
3.
Smith TJ, Bohlke K, Lyman GH et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 33(28), 3199–3212 (2015).
4.
National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Myeloid Growth Factors (2016). www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf.
5.
Aapro MS, Bohlius J, Cameron DA et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur. J. Cancer 47(1), 8–32 (2011).
6.
Potosky AL, Malin JL, Kim B et al. Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J. Natl Cancer Inst. 103(12), 979–982 (2011).
• Study evaluating colony stimulating factor (CSF) use in a multiregional population-based cohort of lung and colorectal cancer patient showing findings that suggest policies to decrease CSF use in patients at lower or intermediate risk of febrile neutropenia may yield substantial cost savings without compromising patient outcomes.
7.
Ramsey SD, Mccune JS, Blough DK et al. Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. Am. J. Manag. Care 16(9), 678–686 (2010).
8.
Crawford J, Dale DC, Kuderer NM et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J. Natl Compr. Canc. Netw. 6(2), 109–118 (2008).
• This study was done to describe the relationship between the occurrence and timing of neutropenic events and chemotherapy treatment and concluded that improved methods of pretreatment assessment of patient risk factors for neutropenia are needed.
9.
Schnipper LE, Smith TJ, Raghavan D et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J. Clin. Oncol. 30(14), 1715–1724 (2012).
• American Society of Clinical Oncology identifies as “don't use white cell stimulating factors for primary prevention of FN (febrile neutropenia) for patients with less than 20% risk for this complication” as one of its top five categories of tests, procedures and/or treatments whose common use and clinical value are not supported by available evidence.
10.
National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Breast Cancer (2016). www.nccn.org/professionals/physician_gls/PDF/breast.pdf.
11.
National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Non-small Cell Lung Cancer (2016). www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
12.
Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N. Eng. J. Med. 325(3), 164–170 (1991).
• Granulocyte colony-stimulating factor as an adjunct to chemotherapy in patients with small-cell cancer of the lung led to reductions in the incidence of febrile neutropenia, in the incidence and duration of grade IV neutropenia and reduced the total number of days of treatment with IV antibiotics and hospitalization.
13.
Pettengell R, Gurney H, Radford JA et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 80(6), 1430–1436 (1992).
14.
Patient-Centered Outcomes Research Institute. Funding Announcement: Improving Methods for Conducting Patient-Centered Outcomes Research (2014). www.pcori.org/sites/default/files/PCORI-PFA-2014-Spring-PFA-Improving-Methods.pdf.
15.
NCORP: NCI Community Oncology Research Program. https://ncorp.cancer.gov/.
16.
National Cancer Institute Community Oncology Research Program. Research Areas (2016). https://ncorp.cancer.gov/research/.
17.
Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J. Clin. Oncol. 25(21), 3158–3167 (2007).
18.
Mccune JS, Sullivan SD, Blough DK et al. Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy. Pharmacotherapy 32(1), 7–19 (2012).
• This retrospective study to determine the impact of primary prophylactic colony-stimulating factor (PP-CSF) use on febrile neutropenia in a patient population receiving contemporary chemotherapy regimens to treat breast, colorectal or non-small-cell lung cancer showed the need for further research studies to evaluate if guideline-directed prescribing of PP-CSFs can improve clinical outcomes.
19.
Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3–4-week chemotherapy regimens in community oncology practices. J. Manag. Care Pharm. 13(4), 337–348 (2007).
20.
Kuderer NM, Lyman GH. Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. J. Natl Cancer Inst. 103(12), 910–913 (2011).
21.
Smith K, Wray L, Klein-Cabral M et al. Ethnic disparities in adjuvant chemotherapy for breast cancer are not caused by excess toxicity in black patients. Clin. Breast Cancer 6(3), 260–266 (2005).
22.
Lyman GH, Kuderer NM, Crawford J et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117(9), 1917–1927 (2011).
23.
Zirpoli GR, Brennan PM, Hong CC et al. Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res. Treat. 137(3), 903–913 (2013).
24.
O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 35(3), 549–556 (1979).
Information & Authors
Information
Published In
Copyright
© Future Medicine Ltd.
History
Published online: 7 July 2017
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study. (2017) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2017-0005
Export citation
Select the citation format you wish to export for this article or chapter.